Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain: 52-week data from the PREDICTIVE™ study in a cohort of French patients with type 1 or type 2 diabetes

Diabetes and Metabolism

Volumn 35, Issue 6, 2009, Pages 469-475

  Marre, M ^a   Pinget, M ^b   Gin, H ^c   Thivolet, C ^d   Hanaire, H ^e   Robert, J J ^f   Fontaine, P ^g  

^a BICHAT HOSPITAL   (France)

^b HÔPITAL CIVIL   (France)

^c HAUT LÉVÊQUE HOSPITAL   (France)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e CHU RANGUEIL   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

^g LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Analogue; Efficacy; Insulin detemir; Tolerability; Type 1 diabetes; Type 2 diabetes

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN DETEMIR;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY WEIGHT; DIABETIC PATIENT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROENTERITIS; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INJECTION SITE REACTION; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PNEUMONIA; SIDE EFFECT; TREATMENT DURATION; WEIGHT GAIN;

ADULT; AGED; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; FRANCE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 71149119593     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabet.2009.06.004     Document Type: Article

References (47)

1. Chapman T.M., and Perry C.M. Spotlight on insulin detemir in type 1 and 2 diabetes mellitus. BioDrugs 19 (2005) 67-69
2. Home P., and Kurtzhals P. Insulin detemir: from concept to clinical experience. Expert Opin Pharmacother 7 (2006) 325-343
3. Vague P., Selam J.L., Skeie S., De Leeuw I., Elte J.W., Haahr H., et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 26 (2003) 590-596
4. Home P., Bartley P., Russell-Jones D., Hanaire-Broutin H., Heeg J.E., Abrams P., et al. Study to evaluate the administration of detemir insulin efficacy. Safety and Suitability (STEADINESS) Study Group. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial. Diabetes Care 27 (2004) 1081-1087
5. Russell-Jones D., Simpson R., Hylleberg B., Draeger E., and Bolinder J. Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen. Clin Ther 26 (2004) 724-736
6. De Leeuw I., Vague P., Selam J.-L., Skeie S., Lang H., Draeger E., et al. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab 7 (2005) 73-82
7. Pieber T.R., Draeger E., Kristensen A., and Grill V. Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin. Diabet Med 22 (2005) 850-857
8. Kolendorf K., Ross G.P., Pavlic-Renar I., Perriello G., Philotheou A., Jendle J., et al. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes. Diabet Med 23 (2006) 729-735
9. Hermansen K., Fontaine P., Kukolja K.K., Peterkova V., Leth G., and Gall M.A. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 47 (2004) 622-629
10. Robertson K.J., Schoenle E., Gucev Z., Mordhorst L., Gall M.A., and Ludvigsson J. Insulin detemir compared with NPH insulin in children and adolescents with Type 1 diabetes. Diabet Med 24 (2007) 27-34
11. Bartley P.C., Bogoev M., Larsen J., and Philotheou A. Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial. Diabet Med 25 (2008) 442-449
12. Philis-Tsimikas A., Charpentier G., Clauson P., Ravn G.M., Roberts V.L., and Thorsteinsson B. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 28 (2006) 1569-1581
13. Hermansen K., Davies M., Derezinski T., Martinez Ravn G., Clauson P., and Home P. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabet Care 29 (2006) 1269-1274
14. Rosenstock J., Davies M., Home P.D., Larsen J., Koenen C., and Schernthaner G. A randomized, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 51 (2008) 408-416
15. Haak T., Tiengo A., Draeger E., Suntum M., and Waldhausl W. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabet Obes Metab 7 (2005) 56-64
16. Rašlová K., Bogoev M., Raz I., Leth G., Gall M.A., and Hancu N. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabet Res Clin Pract 66 (2004) 193-201
17. Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;29:977-86.
18. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPD33). Lancet 1998;352:837-53.
19. Nathan D.M., Buse J.B., Davidson M.B., Holman R.R., Sherwin R., and Zinman B. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabet Care 31 (2008) 1-11
20. Ligthelm R.J., Borzi V., Gumprecht J., Kawamori R., Wenying Y., and Valensi P. Importance of observational studies in clinical practice. Clin Ther 29 (2007) 1284-1292
21. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes 26 Suppl. 3 (2002) S1-S7
22. Dornhorst A., Luddeke H.-J., Sreenan S., Koenen C., Hansen J.B., Tsur A., et al. Safety and efficacy of insulin detemir in clinical practice: 14-week follow-up data from type 1 and type 2 diabetes patients in the PREDICTIVE™ European cohort. Int J Clin Pract 61 (2007) 523-528
23. Dornhorst A., Lüddeke H.J., Koenen C., Meriläinen M., King A., Robinson A., et al. Transferring to insulin detemir from NPH insulin or insulin glargine in type 2 diabetes patients on basal-only therapy with oral antidiabetic drugs improves glycaemic control and reduces weight gain and risk of hypoglycaemia: 14-week follow-up data from PREDICTIVE™. Diabet Obes Metab 10 (2008) 75-81
24. Dornhorst A., Lüddeke H.J., Honka M., Ackermann R.W., Meriläinen M., Gallwitz B., et al. Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE™ study. Curr Med Res Opin 24 (2008) 369-376
25. Luddeke H.-J., Honka M., Hansen J.B., and King A. Insulin detemir maintains body weight and reduces hypoglycemia while improving glycemic control in type 1 and 2 patients: 6-month results from PREDICTIVE™. 2007b Diabetes 56 Suppl. 1 (2007) A2266 [Abstract]
26. Sreenan S., Aczel S., Merilainen M., and Virkamaki A. Transferring the basal component of basal-bolus therapy from NPH insulin to insulin detemir improves glycemic control reduces hypoglycemia and bodyweight in type 1 and 2 patients: 6-month results from PREDICTIVE™. Diabetes 56 Suppl. 1 (2007) A2197 [Abstract]
27. Dornhorst A., Sreenan S., Ackermann R.W., and Hansen J.B. Once-daily insulin detemir improves glycemic control and tolerability in patients with types 1 or 2 diabetes enrolled for 26 weeks in the PREDICTIVE™ study. Diabetes 56 Suppl. 1 (2008) A2112 [Abstract]
28. Luddeke H.-J., Sreenan S., Aczel S., Maxeiner S., Yenigun M., Kozlovski P., et al. PREDICTIVE™ - a global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: baseline characteristics and predictors of hypoglycaemia from the European cohort. Diabet Obes Metab 9 (2007) 428-434
29. Concato J. Observational versus experimental studies: What's the evidence for a hierarchy?. NeuroRx 1 (2004) 341-347
30. Farooqi A., Dodd L., Stribling B., Jarvis J., Davies M.J., and Khunti K. Diabetes service provision in primary care: a baseline survey in a city Primary Care Trust (PCT). Pract Diabet Int 21 (2004) 13-17
31. Peyrot M., Rubin R.R., Lauritzen T., Skovlund S.E., Snoek F.J., Matthews D.R., et al. Resistance to insulin therapy among patients and providers. Diabet Care 28 (2005) 2673-2679
32. Ligthelm R., and Davidson J. Initiating insulin in primary care-The role of modern premixed formulations. Prim Care Diabet 2 (2008) 9-16
33. Cryer P.E. The barrier of hypoglycemia in diabetes. Diabetes 57 (2008) 3169-3176
34. Polonsky W.H., Anderson B.H., Lohrer P.A., Aponte J.E., Jacobsen A.M., and Cole C.F. Insulin omission in women with IIDM. Diabet Care 17 (1994) 1178-1185
35. Bryden K., Neil A., Mayou R.A., Peveler R.C., Fairburn C.G., and Dunger D.B. Eating habits, body weight and insulin misuse. Diabet Care 22 (1999) 1959-1960
36. Tierney S. Control and disordered eating in type 1 diabetes. Eat Weight Disord 12 (2007) e30-34
37. Chaturvedi N. The burden of diabetes and its complications: trends and implications for intervention. Diab Res Clin Pract 76 Suppl. 1 (2007) S3-12
38. Carver C. Insulin treatment and the problem of weight gain in type 2 diabetes. Diabet Educ 32 (2006) 910-917
39. Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabe Care 24 (2001) 758-767
40. Heise T., and Pieber T.R. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogs based on isoglycemic clamp studies. Diabet Obes Metab 9 (2007) 325-343
41. Le Floch JP, Lévy M, Mosnier-Pudar H, Nobels F, Laroche S, Gonbert S, et al. A comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: the ADAPT™ study. Diabetes Care 2008; doi: dc08-0332v1-0.
42. DeVries J.H., Nattrass M., and Pieber T.R. Refining basal insulin therapy: what have we learned in the age of analogues?. Diabet Metab Res Rev 23 (2007) 441-454
43. Monnier L., Mas E., Ginet C., Michel F., Villon L., Cristol J.P., et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 295 (2006) 1681-1687
44. Muggeo M., Zoppini G., Bonora E., Brun E., Bonadonna R.C., Moghetti P., et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetic patients: the Verona Diabetes Study. Diabet Care 23 (2000) 45-50
45. Kilpatrick E.D., Rigby A.S., and Atkin S.L. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabet Care 29 (2006) 1486-1490
46. Hirsch I.B., and Brownlee M. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes: response to author. Diabet Care 30 (2007) 186-187
47. Monnier L., Colette C., Leiter L., Ceriello A., Hanfield M., Owens D., et al. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes: response to author. Diabet Care 30 (2007) 185-186